Urovant Sciences Ltd. Contracts & Agreements
51 Contracts & Agreements
- Business Finance (12 contracts)
- Business Operations (15)
- Human Resources (15)
- Intellectual Property (3)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (4)
- Co-Promotion Agreement, dated October 6, 2020, by and between the Company and Sunovion Pharmaceuticals, Inc (Filed With SEC on February 12, 2021)
- First Amendment to Market Access Services Agreement, dated December 21, 2020, by and between the Company and Sunovion Pharmaceuticals, Inc (Filed With SEC on February 12, 2021)
- Second Amendment to Market Access Services Agreement, dated January 8, 2021, by and between the Company and Sunovion Pharmaceuticals, Inc (Filed With SEC on February 12, 2021)
- First Amendment to Loan Agreement, dated February 5, 2021, by and between Sumitomo Dainippon Pharma Co., Ltd. and Urovant Sciences Ltd (Filed With SEC on February 9, 2021)
- Agreement and Plan of Merger, dated as of November 12, 2020, among Urovant Sciences Ltd., Sumitovant Biopharma Ltd., and Merger Sub (Filed With SEC on November 13, 2020)
- Voting and Support Agreement, dated as of November 12, 2020, between Urovant Sciences Ltd. and Sumitovant Biopharma Ltd (Filed With SEC on November 13, 2020)
- Market Access Services Agreement, dated June 17, 2020, by and between the Company and Sunovion Pharmaceuticals Inc (Filed With SEC on August 13, 2020)
- Description of Share Capital (Filed With SEC on June 19, 2020)
- Employment Agreement, dated June 1, 2020, by and between Walt Johnston and Urovant Sciences, Inc (Filed With SEC on June 19, 2020)
- Information Sharing and Cooperation Agreement, dated May 21, 2020, by and between Urovant Sciences, Ltd. and Sumitovant Biopharma Ltd (Filed With SEC on May 28, 2020)
- Form of Indemnification Agreement with officers and directors (Filed With SEC on April 6, 2020)
- Separation and Consulting Agreement, dated March 23, 2020, by and between Keith A. Katkin and Urovant Sciences, Inc (Filed With SEC on March 23, 2020)
- Employment Agreement, dated March 23, 2020, by and between James A. Robinson and Urovant Sciences, Inc (Filed With SEC on March 23, 2020)
- Loan Agreement, dated December 27, 2019, by and between Sumitomo Dainippon Pharma Co., Ltd. and Urovant Sciences Ltd (Filed With SEC on December 30, 2019)
- Investor Rights Agreement, dated December 27, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., Urovant Sciences Ltd., and Sumitomo Biopharma Ltd (Filed With SEC on December 30, 2019)
- Letter Agreement, dated October 31, 2019, by and between Sumitomo Dainippon Pharma Co., Ltd. and Urovant Sciences Ltd (Filed With SEC on October 31, 2019)
- Employment Agreement, dated October 28, 2019, by and between Ajay Bansal and Urovant Sciences, Inc (Filed With SEC on October 31, 2019)
- Warrant Agreement, dated September 20, 2019, issued to Hercules Capital, Inc (Filed With SEC on September 25, 2019)
- Urovant Sciences Ltd. 2019 Employee Stock Purchase Plan (Filed With SEC on September 17, 2019)
- Urovant Sciences Ltd. 2017 Equity Incentive Plan, as amended and restated (Filed With SEC on September 17, 2019)
- Sublease Agreement between Roivant Sciences, Inc. and Urovant Sciences, Inc. dated June 10, 2019 (Filed With SEC on August 14, 2019)
- Description of Securities (Filed With SEC on June 14, 2019)
- Unconditional Secured Guaranty, dated February 20, 2019, by and between Hercules Capital, Inc. and Urovant Sciences, Inc (Filed With SEC on June 14, 2019)
- Loan and Security Agreement, dated February 20, 2019, by and among Hercules Capital, Inc., Urovant Sciences Ltd., Urovant Holdings Limited, Urovant Sciences GmbH and Urovant... (Filed With SEC on June 14, 2019)
- Warrant Agreement, dated February 20, 2019, issued to Hercules Capital, Inc (Filed With SEC on February 22, 2019)
- Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2017 Equity Incentive Plan, as amended and restated (Filed With SEC on February 14, 2019)
- 2017 Equity Incentive Plan, as amended and restated (Filed With SEC on September 17, 2018)
- Forms of Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan, as amended and restated (Filed With SEC on September 17, 2018)
- Form of Early Exercise Stock Purchase Agreement under the 2017 Equity Incentive Plan, as amended and restated (Filed With SEC on September 17, 2018)
- Employment Agreement, dated September 13, 2018, by and between Christine G. Ocampo and Urovant Sciences, Inc (Filed With SEC on September 17, 2018)
- Employment Agreement, dated September 13, 2018, by and between Nori Ebersole and Urovant Sciences, Inc (Filed With SEC on September 17, 2018)
- Employment Agreement, dated September 13, 2018, by and between Cornelia Haag-Molkenteller, M.D., Ph.D. and Urovant Sciences, Inc (Filed With SEC on September 17, 2018)
- Employment Agreement, dated September 13, 2018, by and between Michael McFadden and Urovant Sciences, Inc (Filed With SEC on September 17, 2018)
- Employment Agreement, dated September 13, 2018, by and between Bryan E. Smith and Urovant Sciences, Inc (Filed With SEC on September 17, 2018)
- License Agreement, dated February 3, 2017, by and between Urovant Sciences GmbH and Merck Sharp & Dohme Corp., as amended on April 27, 2017 and March 19, 2018 (Filed With SEC on September 10, 2018)
- Collaboration Agreement, dated as of August 24, 2017, by and between Urovant Sciences GmbH and Kyorin Pharmaceutical Co., Ltd (Filed With SEC on September 10, 2018)
- Enzyme Supply Agreement, effective as of September 1, 2017, by and between Urovant Sciences GmbH and Codexis, Inc (Filed With SEC on September 10, 2018)
- Form of Underwriting Agreement (Filed With SEC on August 30, 2018)
- License Agreement, dated August 24, 2018, by and between Urovant Sciences GmbH and Ion Channel Innovations, LLC (Filed With SEC on August 30, 2018)
- Form of Indemnification Agreement with directors and executive officers (Filed With SEC on August 30, 2018)
- Employment Agreement, dated September 14, 2017, by and between Keith A. Katkin and Urovant Sciences, Inc (Filed With SEC on August 30, 2018)
- License Agreement, dated February 3, 2017, by and between Urovant Sciences GmbH and Merck Sharp & Dohme Corp., as amended on April 27, 2017 and March 19, 2018 (Filed With SEC on July 13, 2018)
- Collaboration Agreement, dated as of August 24, 2017, by and between Urovant Sciences GmbH and Kyorin Pharmaceutical Co., Ltd (Filed With SEC on July 13, 2018)
- China IP Purchase Agreement, effective as of June 12, 2017, by and between Urovant Sciences GmbH and Roivant Sciences GmbH, as amended on May 22, 2018 (Filed With SEC on July 13, 2018)
- Collaboration Agreement, dated June 1, 2018, by and between Urovant Sciences GmbH and Roivant Sciences GmbH (Filed With SEC on July 13, 2018)
- Enzyme Supply Agreement, effective as of September 1, 2017, by and between Urovant Sciences GmbH and Codexis, Inc (Filed With SEC on July 13, 2018)
- Amended and Restated Services Agreement, effective as of July 9, 2018, by and among Roivant Sciences, Inc., Urovant Sciences GmbH, Urovant Sciences, Inc. and the Registrant (Filed With SEC on July 13, 2018)
- Amended and Restated Services Agreement, effective as of July 9, 2018, by and among Roivant Sciences GmbH and Urovant Sciences GmbH (Filed With SEC on July 13, 2018)
- Information Sharing and Cooperation Agreement, dated as of July 9, 2018, by and between Roivant Sciences Ltd. and the Registrant (Filed With SEC on July 13, 2018)
- Registration Rights Agreement, dated as of July 7, 2018, by and between Roivant Sciences Ltd. and the Registrant (Filed With SEC on July 13, 2018)
- Data Sharing Agreement, effective as of May 22, 2018, by and between Urovant Sciences GmbH and Datavant, Inc (Filed With SEC on July 13, 2018)
